Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain.

Parkinsonism Relat Disord

Servicio General de Investigación Genómica, Banco de ADN and Departamento de Z.y Biología Celular A., Universidad del País Vasco, Vitoria-Gasteiz, Spain.

Published: December 2007

Herein we describe a comparative clinical and genetic study of Lrrk2-associated parkinsonism in Northern Spain. In our sample from the Basque region, Lrrk2 R1441G and G2019S account for 15 out of 50 kindreds (30%) with familial Parkinson's disease. We observe common founder haplotypes for both R1441G and G2019S carriers. Our findings highlight the importance of Lrrk2 parkinsonism in this population and may have important consequences for its extended Diaspora in North, Central and South Americas.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2007.04.003DOI Listing

Publication Analysis

Top Keywords

lrrk2-associated parkinsonism
8
northern spain
8
r1441g g2019s
8
parkinsonism major
4
major disease
4
disease northern
4
spain describe
4
describe comparative
4
comparative clinical
4
clinical genetic
4

Similar Publications

Background: Extracellular vesicles are easily accessible in various biofluids and allow the assessment of disease-related changes in the proteome. This has made them a promising target for biomarker studies, especially in the field of neurodegeneration where access to diseased tissue is very limited. Genetic variants in the LRRK2 gene have been linked to both familial and sporadic forms of Parkinson's disease.

View Article and Find Full Text PDF

In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson's disease.

Brain

December 2024

Lab of Parkinson's & Other Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona; Institut de Neurociències, Universitat de Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) CB06/05/0018-ISCIII; ES 08036 Barcelona, Spain.

Leucine-rich repeat kinase 2 (LRRK2) inhibition is a promising disease-modifying therapy for LRRK2-associated Parkinson's disease (L2PD) and idiopathic PD (iPD). However, pharmaco-dynamic readouts and progression biomarkers for clinical trials aiming for disease modification are insufficient since no endogenous marker reflecting enhanced kinase activity of the most common LRRK2 G2019S mutation has been reported yet in L2PD patients. Employing phospho-/proteomic analyses we assessed the impact that LRRK2 activating mutations had in peripheral blood mononuclear cells (PBMCs) from a LRRK2 clinical cohort from Spain (n=174).

View Article and Find Full Text PDF

Parkinson's Disease (PD) is a continuingly deteriorating neurological ailment affecting over 8.5 million patients globally as of 2019, and the numbers are expected to keep rising. To aid in identifying therapeutic targets, molecular dynamics simulations are convenient and cost-effective methods for enriching our knowledge of the molecular pathophysiology of diseases.

View Article and Find Full Text PDF
Article Synopsis
  • Pathogenic variants in the LRRK2 gene significantly contribute to Parkinson's disease, but not everyone with these variants develops the disease, suggesting lifestyle and environmental factors play a role.
  • A study analyzed household dust samples from different groups, including patients with and without PD and a healthy control group, identifying over 1,000 chemicals and 163 types of microorganisms, with some shown to be statistically significant in relation to PD.
  • Notably, hazardous chemicals like Bisphenol S were linked to negative effects on mitochondrial function in nerve cells from PD patients, highlighting the potential impact of environmental exposures on Parkinson's disease development.
View Article and Find Full Text PDF

Immunomodulatory properties of hempseed oligopeptides in an LRRK2-associated Parkinson's disease animal model.

Food Funct

November 2024

Department of Pharmacology, Pediatrics, and Radiology, School of Medicine, Universidad de Sevilla, Av Sanchez Pizjuan s/n, 41009 Seville, Spain.

Parkinson's disease (PD) is the second most common neurodegenerative disease, with genetic factors like mutations in the LRRK2 gene being a key cause of late-onset autosomal dominant parkinsonism. Nutritional strategies, such as using bioactive peptides with anti-inflammatory properties from sources like hemp protein, are gaining interest as an alternative to pharmacological therapies. In this study, we used an LRRK2-associated PD mouse model to test the efficacy of a hempseed protein hydrolysate (HPH60A + 15F) with antioxidant and anti-inflammatory properties.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!